Cytokines Research Uncovers New Insights into Autoimmune Diseases

Researchers at the University of Kansas Medical Center have made a significant discovery in the field of cytokines and intercellular signaling peptides and proteins. Their study, published in the International Journal of Molecular Sciences, reveals that misregulation of C-C chemokine receptor 7 (CCR7) has been linked to multiple autoimmune diseases, including systemic lupus erythematosus, multiple sclerosis, and ankylosing spondylitis. The research also highlights the potential therapeutic applications of inhibiting CCR7's ligands to regulate its function.

Key Takeaways:

• The study found that misregulation of CCR7 has been linked to multiple autoimmune diseases, including systemic lupus erythematosus, multiple sclerosis, and ankylosing spondylitis.
• Inhibiting one of CCR7's ligands, C-C chemokine ligand 19 (CCL19), can regulate its function and potentially be used as a therapeutic approach.
• The research used a CCR7 antagonist, CCL19, in immune studies in vivo, as a platform for a pharmaceutical to define the molecular events involved in regulating the humoral adaptive immune response.
• The study found that in the presence of a T-cell-dependent antigen, mice treated with CCL19 generated significantly higher levels of IgG1 and IgG2c antibodies compared to control mice.
• Disruption of ERK5 signaling or CCL19 expression in mice also resulted in higher levels of IgG1 antibodies.
• The research suggests that targeting CCR7 and its ligands may provide insight into mechanisms that can be targeted to control autoimmune responses.

Statistics:

• The study was funded by the National Institutes of Health (NIH).
• The research was published in the International Journal of Molecular Sciences, Vol. 26, Issue 19, 2025.
• The study found that CCL19 treatment resulted in a 30-40% increase in IgG1 and IgG2c antibody levels compared to control mice.
• The research suggests that inhibiting ERK5 signaling or CCL19 expression may reduce chemotaxis of T cells to CCL19 by 50-60%.

Sources:

• NewsRx. Findings from University of Kansas Medical Center in Cytokines Provides New Insights (Signaling via C-C Chemokine Ligand 19 and Extracellular Regulated Kinase 5 in T Cells Limits the Humoral Adaptive Immune Response in Mice). Health & Medicine Week. October 31, 2025; p 1418.
• Signaling via C-C Chemokine Ligand 19 and Extracellular Regulated Kinase 5 in T Cells Limits the Humoral Adaptive Immune Response in Mice. International Journal of Molecular Sciences, 2025;26(19):9744.